Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Erratum

Erratum In the originally published version of this article “mTOR inhibitors improve both humoral and cellular response to SARS‐CoV‐2 messenger RNA BNT16b2 vaccine in kidney transplant recipients,”1 the below funding information was not included.The article has been funded by Open Access Funding provided by Universita degli Studi di Foggia within the CRUI‐CARE Agreement.REFERENCENetti GS, Infante B, Troise D, et al. mTOR inhibitors improve both humoral and cellular response to SARS‐CoV‐2 messenger RNA BNT16b2 vaccine in kidney transplant recipients. Am J Transplant. 2022;22(5):1475‐1482. doi:10.1111/ajt.16958 http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png American Journal of Transplantation Wiley

Erratum

American Journal of Transplantation , Volume Early View – Nov 4, 2022

Loading next page...
 
/lp/wiley/erratum-hf55DJdmDD
Publisher
Wiley
Copyright
© 2022 The American Society of Transplantation and the American Society of Transplant Surgeons
ISSN
1600-6135
eISSN
1600-6143
DOI
10.1111/ajt.17214
Publisher site
See Article on Publisher Site

Abstract

In the originally published version of this article “mTOR inhibitors improve both humoral and cellular response to SARS‐CoV‐2 messenger RNA BNT16b2 vaccine in kidney transplant recipients,”1 the below funding information was not included.The article has been funded by Open Access Funding provided by Universita degli Studi di Foggia within the CRUI‐CARE Agreement.REFERENCENetti GS, Infante B, Troise D, et al. mTOR inhibitors improve both humoral and cellular response to SARS‐CoV‐2 messenger RNA BNT16b2 vaccine in kidney transplant recipients. Am J Transplant. 2022;22(5):1475‐1482. doi:10.1111/ajt.16958

Journal

American Journal of TransplantationWiley

Published: Nov 4, 2022

References